CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today reported financial and operational results for the second quarter ended June 30, 2016.
“This quarter marks a significant strategic step forward for Dicerna as we formally introduced our GalXC™ subcutaneous delivery platform at our June Investor Day. During that event we showed consistent, potent and durable preclinical gene silencing data from GalXC molecules against 12 different disease-associated genes, including six examples of data from non-human primates, to highlight the robust basis for further investigation of the silencing of disease-causing genes in the liver across multiple therapeutic areas,” said Douglas M. Fambrough, Ph.D., president and chief executive officer of Dicerna.
“This quarter marks a significant strategic step forward for Dicerna as we formally introduced our GalXC™ subcutaneous delivery platform at our June Investor Day. During that event we showed consistent, potent and durable preclinical gene silencing data from GalXC molecules against 12 different disease-associated genes, including six examples of data from non-human primates, to highlight the robust basis for further investigation of the silencing of disease-causing genes in the liver across multiple therapeutic areas,” said Douglas M. Fambrough, Ph.D., president and chief executive officer of Dicerna.
